Page 143 - இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. What happened Somewhat of an outlier coronavirus stock, Ocugen (NASDAQ:OCGN) see-sawed in price on Monday. That followed a new analyst recommendation, which although very bullish, likely gave investors pause to think about the company s prospects. So what Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. He also placed a $15 per share target price on the stock, which is more than double the level the shares closed at on Friday.

United statesRobert leboyerNational institute of virologyDrug administrationIndian council of medical researchBharat biotechIndian councilMedical research national instituteBiologics license approvalEmergency use authorizationஒன்றுபட்டது மாநிலங்களில்தேசிய நிறுவனம் ஆஃப் வைராலஜிஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிபாரத் பயோடெக்இந்தியன் சபைமருத்துவ ஆராய்ச்சி தேசிய நிறுவனம்